Mylan CEO, and daughter of a W.Va senator Joe Manchin, Heather Bresh may have evaded a congressional hearing on the topic EpiPen price increases (after all, it may reveal just a little too much about the dirty laundry in form of billions in lobby payments paid by big pharma companies to members of Congress), but her troubles with the judicial branch have just begun: as Bloomberg reported moments ago, the New York Attorney General has just launched an anti-trust probe into Mylan's pricing of EpiPen.

A.G. SCHNEIDERMAN LAUNCHES ANTITRUST PROBE INTO MYLAN ON EPIPEN

Now that the horse is out of the stable, everyone is demanding their pound of flesh.

The stock promptly took a leg lower, as it seems the company is nowhere near out of the woods yet.

And for his next act, we can only assume that the NYAG will focus just as intently on which members of congress received tens of millions in lobby dollars from various pharma companies. As a reminder, according to OpenSecrets, so far in 2016, the amount is $129 million, rising to $2.3 billion over the past decade.

Here is a small selection of the 369 lobbying "clients" OpenSecrets keeps track of: one can see Mylan toward the bottom.